Clinical Trial Update: RE-MODEL Dabigatran Etexilate 150mg or 220mg Once Daily (o.d.) Versus (v.s.) Enoxaparin 40mg o.d. for Prevention of Thrombosis After Knee Surgery [Phase 3]

View source ↗

Summary

Phase 3 trial comparing dabigatran etexilate 150 mg or 220 mg once daily with enoxaparin for prevention of venous thromboembolism after knee replacement; result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Deep Vein Thrombosis
• Pulmonary Embolism
• Venous Thromboembolism

Drugs mentioned

• Lovenox (enoxaparin)
• Pradaxa (dabigatran etexilate)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Arthroplasty, Replacement, Knee, Thromboembolism | Phase 3 | Status: COMPLETED | Results posted: 2010-12-17